Streptococcus pneumoniae polysaccharide conjugated to haemophilus influenzae protein D
Highest phase reached
Approved
Drug type
Vaccine component
First approval year
2009
- First approval year
- 2009
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Vaccine component
- Drug name
- Streptococcus pneumoniae polysaccharide conjugated to haemophilus influenzae protein D
- streptococcus pneumoniae polysaccharide conjugated to haemophilus influenzae protein d component of synflorix
- Streptococcus pneumoniae polysaccharide conjugated to haemophilus influenzae protein d component of synflorix
- streptococcus pneumoniae polysaccharide conjugated to haemophilus influenzae protein d
- Streptococcus pneumoniae polysaccharide conjugated to haemophilus influenzae protein d
- ChEMBL ID
- CHEMBL6068367
- First in class
- No
- Orphan designation
- No
Mechanisms of action
- Mechanism
- Polysaccharide conjugated to Haemophilus influenzae Protein D vaccine antigen
- Action type
- VACCINE_ANTIGEN
- Target
- Polysaccharide conjugated to Haemophilus influenzae Protein D
- Condition
- Pneumococcal Infections
- Highest recorded phase
- 4
- Condition identifier
- EFO:0000772
- Subject identifier
- D011008
- Condition
- Vaccination
- Highest recorded phase
- 4
- Condition identifier
- EFO:0004292
- Subject identifier
- D014611
- Condition identifier
- EFO_1001476
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005114
- Highest recorded phase
- 4
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Natural product
- No
Related records
Trials (38)
- A Study to Compare LBVD to Eupenta and Imovax Polio in Healthy Adults
- A Study to Learn About a Type of Pneumococcal Vaccine With a New Ingredient (PF-07872411) Intended to Enhance the Effects of the Vaccine Which is Given to Adults
- A Study to Learn About How a New Pneumococcal Vaccine Works in Infants
- A Study to Learn How Effective is PCV20 to Help Stop Adults Who Have a Higher Chance of Getting Pneumonia
- A Study to Learn More About Prevenar 20 Once it is Out in the Korean Market
- Assess Reacto- and Immunogenicity of Pneumococcal Conjugate Vaccine When Given as Booster or a 2 Dose Catch up Schedule
- Assessment of Novel Pneumococcal Conjugate Vaccination Scheduled in UK Infants
- Clinical Trial of the 24-valent Pneumococcal Polysaccharide Conjugate Vaccine (CRM197/Tetanus Toxoid)
- Dose-Finding Study of S.Pneumoniae Whole Cell Vaccine Adsorbed to Alum (PATH-wSP) in Healthy Kenyan Adults and Toddlers
- Immunogenicity and Safety of GlaxoSmithKline Biologicals' Infanrix™-IPV+Hib Vaccine
- Immunogenicity and Safety of Meningococcal Vaccine GSK 134612 Co-administered With Pneumococcal and DTPa-HBV-IPV/Hib Vaccines
- Immunogenicity and Safety of Two Formulations of GSK Biologicals' Pneumococcal Vaccine (2830929A and 2830930A) When Administered in Healthy Infants
- Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' 10-valent Pneumococcal Conjugate Vaccine
- Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Pneumococcal Vaccine (Synflorix™) When Administered to Children Who Are at an Increased Risk of Pneumococcal Infection
- Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine Administered as a Booster Dose
- Immunogenicity of a Reduced Primary Schedule for Pneumococcal Conjugate Vaccine in UK Infants
- Impact of GSK Biologicals' 2189242A Vaccine on Nasopharyngeal Carriage, Safety & Immunogenicity in Children & Infants
- PCV24 Clinical Trial in Infants and Young Children Aged 2 Months (Minimum 6 Weeks) to 71 Months
- Phase 2 Trial to Evaluate Safety and Immunogenicity of Inventprise's (IVT) 25-valent Pneumococcal Conjugate Vaccine (IVT PCV-25) in Healthy Infants
- Phase 3 Study of 10-valent Pneumococcal Conjugate Vaccine (PNEUMOSIL) in Healthy Infants
Approved for (1)
In development for (1)
- Streptococcal infection Phase 3